Clinical Trial

Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA

Study acronym: DECREASE
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 21, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
Darolutamide is a drug that has a proven survival benefit in non-metastatic (M0) castrate resistant prostate cancer when using conventional imaging. However, it is estimated that \>90% of patients have disease apparent when using PSMA PET. This study investigates the use of local consolidation radiotherapy in this cohort of men.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2020-03-22; most recent amendment 2025-08-19.
Status change: Recruiting → Active, Not Recruiting 2025-08-19
Status change: Not Yet Recruiting → Recruiting 2021-08-26
Trial Details
NCT Number NCT04319783
Lead Sponsor Trans Tasman Radiation Oncology Group
Collaborators: Bayer, Peter MacCallum Cancer Centre, Australia
Conditions Advanced Prostate Carcinoma, Cancer of Prostate, PSA, Castrate Resistant Prostate Cancer
Enrollment 65 participants
Start Date 2021-06-02
Primary Completion 2026-06 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-08-21